Neuronetics Inc (NASDAQ:STIM) insider Daniel Guthrie sold 3,685 shares of the firm’s stock in a transaction on Wednesday, May 22nd. The stock was sold at an average price of $14.53, for a total transaction of $53,543.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
NASDAQ STIM traded down $0.54 during trading hours on Thursday, reaching $14.04. 90,730 shares of the company’s stock traded hands, compared to its average volume of 110,649. Neuronetics Inc has a 52-week low of $13.26 and a 52-week high of $39.39. The stock has a market cap of $273.34 million and a P/E ratio of -5.22. The company has a debt-to-equity ratio of 0.52, a current ratio of 8.94 and a quick ratio of 8.74.
Neuronetics (NASDAQ:STIM) last issued its quarterly earnings results on Tuesday, May 7th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.05). Neuronetics had a negative net margin of 47.21% and a negative return on equity of 1,385.60%. The business had revenue of $12.73 million for the quarter, compared to analysts’ expectations of $12.72 million. Research analysts expect that Neuronetics Inc will post -1.64 earnings per share for the current fiscal year.
Several equities research analysts have recently commented on the stock. Zacks Investment Research raised shares of Neuronetics from a “sell” rating to a “hold” rating in a research report on Wednesday, May 8th. BTIG Research reaffirmed a “buy” rating and issued a $25.00 target price on shares of Neuronetics in a research report on Wednesday, March 6th. Finally, Piper Jaffray Companies dropped their target price on shares of Neuronetics from $35.00 to $28.00 and set an “overweight” rating for the company in a research report on Tuesday, March 5th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $31.60.
Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States, Japan, and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.
Read More: Beige Book
Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.